Clinical data
Other namesJ-113,397
  • 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one
CAS Number
PubChem CID
Chemical and physical data
Molar mass399.579 g·mol−1
3D model (JSmol)
  • C4CCCCCCC4CN(CC1CO)CCC1n3c2ccccc2n(CC)c3=O
  • InChI=1S/C24H37N3O2/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19/h8-9,12-13,19-21,28H,2-7,10-11,14-18H2,1H3/t20-,21+/m0/s1 ☒N
 ☒NcheckY (what is this?)  (verify)

J-113,397 is an opioid drug which was the first compound found to be a highly selective antagonist for the nociceptin receptor, also known as the ORL-1 receptor.[1][2] It is several hundred times selective for the ORL-1 receptor over other opioid receptors,[3][4] and its effects in animals include preventing the development of tolerance to morphine,[5] the prevention of hyperalgesia induced by intracerebroventricular administration of nociceptin (orphanin FQ),[6] as well as the stimulation of dopamine release in the striatum,[7] which increases the rewarding effects of cocaine,[8] but may have clinical application in the treatment of Parkinson's disease.[9][10][11]


Patents for treating arrhythmia:[12]

Improved synthesis:[13] Additional patents:[14][15]

Condensation between 1-Benzyl-3-methoxycarbonyl-4-piperidone [57611-47-9] (1) and O-Phenylenediamine (2) gives CID:16726310 (3). Reaction with boc anhydride followed by treatment with trifluoroacetic acid gives CID:16726358 (4). Reaction with iodoethane in the presence of base alkylates the urea nitrogen giving CID:16726359 (5). Reduction of the enamine by treatment with magnesium metal in methanol solvent occurs to give predominantly the trans isomer, CID:16726360 (6). Catalytic removal of the benzyl group gives CID:16726362 (7). Reductive amination with Cyclooctanecarbaldehyde [6688-11-5] (7) gives CID:16726364 (9). Lastly, reduction of the ester with lithium aluminium hydride completed the synthesis of J-113397 (10).

See also


  1. ^ Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, et al. (December 1999). "Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397)". Journal of Medicinal Chemistry. 42 (25): 5061–3. doi:10.1021/jm990517p. PMID 10602690.
  2. ^ De Risi C, Piero Pollini G, Trapella C, Peretto I, Ronzoni S, Giardina GA (July 2001). "A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist". Bioorganic & Medicinal Chemistry. 9 (7): 1871–7. doi:10.1016/s0968-0896(01)00085-2. PMID 11425589.
  3. ^ Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Iwasawa Y, Ohta H (January 2000). "A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397". European Journal of Pharmacology. 387 (3): R17-8. doi:10.1016/s0014-2999(99)00822-5. PMID 10650183.
  4. ^ Smith ED, Ariane Vinson N, Zhong D, Berrang BD, Catanzaro JL, Thomas JB, et al. (January 2008). "A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay". Bioorganic & Medicinal Chemistry. 16 (2): 822–9. doi:10.1016/j.bmc.2007.10.023. PMC 2323199. PMID 17976996.
  5. ^ Chung S, Pohl S, Zeng J, Civelli O, Reinscheid RK (July 2006). "Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance". The Journal of Pharmacology and Experimental Therapeutics. 318 (1): 262–7. doi:10.1124/jpet.106.103960. PMID 16595734. S2CID 15569763.
  6. ^ Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, et al. (August 2000). "In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist". European Journal of Pharmacology. 402 (1–2): 45–53. doi:10.1016/s0014-2999(00)00520-3. PMID 10940356.
  7. ^ Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, et al. (July 2004). "Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior". The Journal of Neuroscience. 24 (30): 6659–66. doi:10.1523/JNEUROSCI.0987-04.2004. PMC 6729727. PMID 15282268.
  8. ^ Marquez P, Nguyen AT, Hamid A, Lutfy K (March 2008). "The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine". Neuropharmacology. 54 (3): 564–8. doi:10.1016/j.neuropharm.2007.11.003. PMC 2276976. PMID 18082848.
  9. ^ Marti M, Trapella C, Viaro R, Morari M (February 2007). "The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway". The Journal of Neuroscience. 27 (6): 1297–307. doi:10.1523/JNEUROSCI.4346-06.2007. PMC 6673573. PMID 17287504.
  10. ^ Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M (June 2008). "Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism". Neurobiology of Disease. 30 (3): 430–8. doi:10.1016/j.nbd.2008.02.011. PMC 2605654. PMID 18413287.
  11. ^ Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH (October 2008). "The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease". Movement Disorders. 23 (13): 1922–5. doi:10.1002/mds.22086. PMID 18759357. S2CID 46116472.
  12. ^ Guo Zheng, et al. CN 111249279  & CN 111265663  (2020).
  13. ^ Sulima, A., Folk, J., Jacobson, A., Rice, K. (2 May 2007). "A New Approach to the Synthesis of the Nonpeptide NOP Receptor Antagonist J-113397". Synthesis. 2007 (10): 1547–1553. doi:10.1055/s-2007-966037.
  14. ^ Satoshi Ozaki, et al. WO 1998054168  (to MSD KK).
  15. ^ Hiroshi Kawamoto, et al. WO 2000031061  (to MSD KK).